Bixiye
QP10-20 Pharmacy Benefit Exclusion for Xenleta TM, Asparlas TM, Ogivri TM and Tranexamic Acid/Sodium Chloride
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2101 - 2110 ee natiijooyinka 3613
Bixiye
QP9-20 Pharmacy Benefit Exclusion Healthcare Administered Drugs
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP15-20 Commercial Medical Drug Exclusion List Expanded to Include Avsola
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP14-20 New Service Type Options for Inpatient Admission Notifications on Availity Portal
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP13-20 Blue Cross Blue Shield National Coordination of Care SM Overview
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP6-20 Separate Remits Will be Sent for Processed Legacy Platform Runout Claims
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP7-20 Pharmacy Benefit Exclusion for Vyondys 53 (golodirsen)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP1-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) Criteria: Palforzia and Viaskin Peanut (Peanut Allery Oral Immunotherapy)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP4-20 Minnesota Health Care Programs (MHCP) and Minnesota Senior Health Options (MSHO) Behavioral Health Fax Back Notification Update
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP5-20 Pharmacy Benefit Exclusions
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020